Advertisement
MRK vs NVS
Which Stock Would AI Choose? Merck & Co., Inc. (MRK) vs. Novartis AG (NVS) Stock Comparison
Key Takeaways
- MRK has delivered a sharply stronger recent rally, but its forward P/E (price-to-earnings) multiple sits at a premium as investors price in a post-Keytruda pipeline.
- NVS offers a more modest valuation and a higher dividend, yet its recent stock behavior has been dented by back-to-back late-stage trial failures and generic erosion.
- Both companies face patent-exclusivity pressure on flagship franchises, but Merck's single-drug concentration on Keytruda is more acute than Novartis's broader portfolio spread.
- Novartis's newer growth drivers (Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix) are delivering commercially now, while several of Merck's most promising assets are still earlier-stage.
- Relative performance has favored MRK over the past year, but NVS is more diversified and trades at a lower earnings multiple, a meaningful trade-off for investors.
Introduction
This stock comparison examines two of the world's largest pharmaceutical companies, Merck & Co., Inc. (MRK) and Novartis AG (NVS), to help traders and investors evaluate their market positioning in the current environment. Both companies are navigating patent expirations on legacy blockbusters while attempting to build the next generation of growth medicines. Their contrasting recent performance and valuations make them a useful paired study: Merck has rallied sharply on pipeline optimism, while Novartis has traded more defensively amid clinical setbacks. Investors focused on relative performance, growth-versus-value trade-offs, and pipeline catalysts may find this side-by-side review especially relevant.
MRK Overview and Recent Performance
Merck & Co., Inc. is a U.S.-based global healthcare company whose oncology franchise, led by Keytruda, still accounts for roughly half of total revenue. In recent weeks, MRK has been one of the standout performers in large-cap pharmaceuticals, with shares rising roughly 50% year to date and approaching 52-week highs before a modest pullback. The rally has been driven less by current earnings than by pipeline momentum: positive Phase III data in melanoma for an investigational combination with Moderna, regulatory approvals including the first oral PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor for lowering LDL cholesterol, and accelerating sales of Winrevair, its pulmonary arterial hypertension (PAH) treatment. Management has pointed to more than $70 billion of commercial opportunity across over 20 new products by the mid-2030s, a narrative investors have rewarded. However, the stock's premium valuation and concentration risk ahead of Keytruda's expected 2028 loss of exclusivity remain central watchpoints.
NVS Overview and Recent Performance
Novartis AG is a Swiss pharmaceutical company organized around four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. Unlike Merck, NVS has not enjoyed the same stock momentum, trading roughly flat year to date. Its newer growth medicines are performing well commercially — Kisqali (breast cancer), Kesimpta (multiple sclerosis, or MS), Pluvicto (prostate cancer), Leqvio (cholesterol), and Scemblix (chronic myeloid leukemia, or CML) are all growing at double-digit rates — but generic competition has eroded sales of older blockbusters such as Entresto and Promacta. Sentiment has also been weighed down by two late-stage trial failures within a single week and a prominent shareholder's call for a board overhaul. Novartis has guided to low single-digit sales growth and a low single-digit decline in core operating income for 2026, reflecting a transition period rather than a breakout.
Trending AI Robots
For traders seeking a more systematic approach to names like these, Tickeron's Trending AI Robots page offers a curated view of the platform's AI trading bots. Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and set of traded symbols. Because not every bot suits every market environment, only the most suitable performers for current conditions are featured in this curated section, giving users a focused entry point into the platform's broader offering. Explore the Trending AI Robots page to review the bots that are currently standing out.
Head-to-Head Comparison
The two companies present sharply different risk-and-return profiles. MRK carries heavier single-asset concentration, with Keytruda still the dominant revenue driver, yet its recent momentum and pipeline catalysts have been stronger, and investors have assigned it a premium forward P/E multiple. NVS is more diversified across four therapeutic areas and trades at a notably lower forward P/E while paying a higher dividend yield, but it faces immediate generic erosion on Entresto and has absorbed credibility damage from late-stage trial failures.
On growth drivers, Novartis's newer medicines are already generating billions in revenue, whereas several of Merck's most touted pipeline assets remain earlier in their commercial trajectory. On sentiment, Merck's market positioning has been lifted by a steady cadence of approvals and data readouts, while Novartis is contending with execution and governance questions. In sector exposure, both are pure-play innovators in prescription medicines, but Merck's heavier oncology weighting contrasts with Novartis's broader spread across cardiovascular, immunology, neuroscience, and oncology.
Tickeron AI Verdict
Based on observable trend consistency, relative momentum, and catalyst positioning, Tickeron's AI would likely lean toward MRK in the current environment. Merck has demonstrated more persistent upward price momentum, a richer pipeline catalyst schedule, and stronger recent relative performance against both the sector and NVS. That said, its premium valuation and single-franchise concentration introduce a higher degree of downside sensitivity to any pipeline disappointment. Novartis offers superior diversification and a more favorable valuation, but its trend has been less consistent amid clinical setbacks and generic pressure. In probabilistic terms, the AI would favor Merck for trend and catalyst momentum, while recognizing Novartis as the more defensively positioned alternative.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Buy and NVS is a Buy.
Momentum Indicator for MRK turns positive, indicating new upward trend
MRK saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 52 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 32 of 52 cases where MRK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
Following a +2.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 193 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
MRK moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 25%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 30 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.451) is normal, around the industry mean (-3.218). MRK's P/E Ratio (113.992) is considerably higher than the industry average of (20.770). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.042) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
NVS's RSI Oscillator recovers from oversold territory
The RSI Indicator for NVS moved out of oversold territory on September 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 15 of the 24 cases the stock moved higher. This puts the odds of a move higher at 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 40 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 49%.
The Moving Average Convergence Divergence (MACD) for NVS just turned positive on September 24, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in 27 of 46 cases over the following month. The odds of a continued upward trend are 59%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 182 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
NVS broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.872) is normal, around the industry mean (-3.218). P/E Ratio (22.519) is within average values for comparable stocks, (20.770). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.126) as compared to the industry average of (0.042). P/S Ratio (4.715) is also within normal values, averaging (4.033).
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
MRK | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 72 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 30 | 7 | |
SMR RATING 1..100 | 79 | 33 | |
PRICE GROWTH RATING 1..100 | 38 | 47 | |
P/E GROWTH RATING 1..100 | 1 | 22 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (9) in the Pharmaceuticals Major industry is significantly better than the same rating for MRK (88). This means that NVS’s stock grew significantly faster than MRK’s over the last 12 months.
NVS's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is in the same range as MRK (30). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.
NVS's SMR Rating (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (79). This means that NVS’s stock grew somewhat faster than MRK’s over the last 12 months.
MRK's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as NVS (47). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is in the same range as NVS (22). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.
| MRK | NVS | |
|---|---|---|
| RSI ODDS (%) | N/A | 7 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 62% | 2 days ago 44% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 49% |
| MACD ODDS (%) | N/A | 2 days ago 59% |
| TrendWeek ODDS (%) | 2 days ago 49% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 42% | 2 days ago 51% |
| Advances ODDS (%) | 14 days ago 57% | 5 days ago 54% |
| Declines ODDS (%) | 8 days ago 51% | 15 days ago 45% |
| BollingerBands ODDS (%) | 2 days ago 60% | 2 days ago 35% |
| Aroon ODDS (%) | N/A | 2 days ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 2 FA rating(s) are green while NVS’s FA Score has 4 green FA rating(s).
- MRK’s FA Score: 2 green, 3 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).
- MRK’s TA Score: 4 bullish, 3 bearish.
- NVS’s TA Score: 6 bullish, 4 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а -1.25% price change this week, while NVS (@Pharmaceuticals: Major) price change was +4.42% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.33%. For the same industry, the average monthly price growth was -4.81%, and the average quarterly price growth was +5.40%.
Reported Earning Dates
MRK is expected to report earnings on Oct 29, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+3.33% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with JNJ. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then JNJ could also see price increases.
| Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
|---|---|---|---|---|
| MRK | 100% | -1.59% | ||
| JNJ - MRK | 50% Loosely correlated | -0.69% | ||
| GSK - MRK | 50% Loosely correlated | -0.10% | ||
| AMGN - MRK | 47% Loosely correlated | -1.75% | ||
| NVS - MRK | 47% Loosely correlated | -0.28% | ||
| BIIB - MRK | 46% Loosely correlated | +0.36% | ||
More | ||||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.